Daniel Capon, PhD

Chief Scientific Officer at Hinge Bio, Inc.

Speaker

Dr. Daniel Capon is the lead inventor of three technologies that have revolutionized biological therapy: Fc fusion proteins, scFv-zeta chimeric antigen receptors for cell therapy, and germline-modified mice producing repertoires of fully human antibodies against human disease targets. He is currently the Chief Scientific Officer at Hinge Bio, Inc., where he and his colleagues are developing his latest invention of Tetrahedral Antibodies for human therapy. Dr. Capon completed his doctoral studies at M.I.T and shared the 1989 Boehringer Ingelheim Award for “Subtypes of Muscarinic Receptors” and the 1999 Intellectual Property Owners Distinguished Inventor Award for “Factor VIII for Hemophilia”.